

SEEKR2: Versatile Multiscale Milestoning Utilizing the OpenMM Molecular Dynamics Engine

Lane W. Votapka, Andrew M. Stokely, Anupam A. Ojha, and Rommie E. Amaro*



Cite This: *J. Chem. Inf. Model.* 2022, 62, 3253–3262



Read Online

ACCESS |



Metrics & More



Article Recommendations



Supporting Information

ABSTRACT: We present SEEKR2 (simulation-enabled estimation of kinetic rates version 2)—the latest iteration in the family of SEEKR programs for using multiscale simulation methods to computationally estimate the kinetics and thermodynamics of molecular processes, in particular, ligand-receptor binding. SEEKR2 generates equivalent, or improved, results compared to the earlier versions of SEEKR but with significant increases in speed and capabilities. SEEKR2 has also been built with greater ease of usability and with extensible features to enable future expansions of the method. Now, in addition to supporting simulations using NAMD, calculations may be run with the fast and extensible OpenMM simulation engine. The Brownian dynamics portion of the calculation has also been upgraded to Browndye 2. Furthermore, this version of SEEKR supports hydrogen mass repartitioning, which significantly reduces computational cost, while showing little, if any, loss of accuracy in the predicted kinetics.



INTRODUCTION

Background. The ability to computationally predict kinetic quantities, such as rate constants of reactions involving biomacromolecules, remains an active pursuit in computational and theoretical biophysics.^{1–9} Many approaches rely on sampling possible reaction pathways using simulation methods such as molecular dynamics (MD)^{10–17} and Brownian dynamics (BD);^{18–22} however, the main challenge arises from the need to sample many MD simulation trajectories to obtain accurate predictions for important kinetic quantities, such as the k_{off} .²³ At present, the amount of brute force MD simulations required to obtain kinetics of ligand binding and unbinding remains intractable for most applications involving biologically relevant targets. Therefore, many clever approaches to avoid the cost of brute force MD simulations use a wide variety of schemes to expand the temporal and spatial reach available to the computational biophysics community to predict kinetic quantities. We, and others, have summarized these approaches elsewhere.^{24–43}

SEEKR is one method we developed to utilize both MD and BD approaches such that we may not only exploit MD when explicit solvent and full molecular flexibility are required but also exploit BD's speed when semi-rigid body molecules and implicit solvents will suffice.^{44–47} SEEKR accomplishes this by partitioning the phase space of a system into smaller regions and then simulating trajectories within these regions using whichever is the most appropriate simulation approach, allowing each region to be simulated in parallel. The question of how to determine the best partitions of the MD and BD regions is still not completely understood, although we surmise that the BD region should extend beyond the first, and probably second, solvation shell to minimize inaccuracies caused by the implicit solvent. Within the solvation shells and the binding site itself, the explicit solvent and molecular

flexibility of MD are likely required to obtain reasonable thermodynamic and kinetic quantities. In addition, by partitioning the phase space of molecular motion into smaller regions, one may ensure that events that are kinetically relevant but often rare are adequately observed and characterized. The statistics obtained from short simulations in each of these smaller regions are then stitched together using milestoning theory.^{23,48–51}

SEEKR performed well in predicting ligand-receptor kinetics^{44,52} and was mostly successful in rank-ordering the affinity and residence times of a series of ligands binding to a receptor.^{46,47} The SEEKR approach was further augmented by utilizing a newer modification to milestoning theory, Markovian milestoning with Voronoi tessellations (MMVT).⁴⁶ MMVT-SEEKR performed comparably well to the classical milestoning approach used in the earlier versions, with some added benefits, including an increase in accuracy for some quantities and decreased computational cost. All previous versions of SEEKR, including the MMVT version, used the NAMD simulation software package for MD.⁵³

Here, we present SEEKR2, which uses the OpenMM simulation software suite⁵⁴ for MD as an alternative to NAMD. OpenMM has enjoyed skyrocketing popularity among the scientific community because of its python interface, ease of extensibility, competitive performance on GPUs, and active development community. In addition, the design of OpenMM

Received: April 27, 2022

Published: June 27, 2022



makes it relatively easy to develop independent plugins. Using SEEKR2, one may perform the MD portion of the SEEKR protocol in either OpenMM or NAMD, using either MMVT or the conventional milestone method as developed by Elber and colleagues.^{23,48,49}

SEEKR2 supports hydrogen mass repartitioning (HMR),⁵⁵ allowing one to use a timestep of up to 4 fs. HMR works by repartitioning some of the mass of a heavy atom bonded to a hydrogen onto the hydrogen atom, enabling one to use a larger timestep without causing numerical instability in the simulation. Theory shows that HMR correctly produces thermodynamic quantities; however, its effect on kinetic quantities is unclear. A recent publication asserts that using HMR does not significantly affect kinetics in diffusing systems.⁵⁶ We show in a later section that HMR produces reasonable kinetic results for systems within SEEKR2.

Design and Implementation. *The SEEKR2 OpenMM Plugin.* The SEEKR2 OpenMM plugin design is based on OpenMM's own layered architecture; it contains: (i) a Python interface layer for easy interactions with the user, (ii) CPU and GPU kernels, which include a number of integrators that implement the dynamics defined by MMVT or Elber milestone, and (iii) a C++ API layer to connect the Python layer with the kernels.

A key aspect of the MMVT protocol is the definition of Voronoi cells. When a system reaches one of the boundaries of the cell, it collides against the boundary, and the identities and timescales of these collisions are logged for eventual analysis. SEEKR2 leverages the powerful custom mathematical expressions within the OpenMM package to define the locations of Voronoi cells and boundaries. By supplying a mathematical expression, the user can define the boundaries of a Voronoi cell, and when the system crosses it, the integrator logs the crossing information, the atomic positions and velocities are restored to the previous step, and velocities are reversed.

The mathematical expression for a given boundary defines a function, which can be any function of the system atomic positions. The functions for a cell (one function for each boundary) are defined by the user such that, when the system is inside the cell, the boundary function is negative. However, if the system ever crosses the boundary, then the value of the boundary function is positive for that system configuration. This makes the boundary a level set (or implicit surface). While more complicated than a simple Voronoi cell description, a level set description of a boundary is more general (able to define Voronoi cells and more), and SEEKR2 automates the most common milestone shapes that a user is likely to require. Such custom mathematical expressions make it straightforward to define Voronoi cells and boundaries in high-dimensional spaces.

An additional feature of the plugin allows users to optionally save OpenMM state objects whenever the boundary is crossed. These states can be used to analyze or visualize the locations of MMVT collisions or as a starting set of atomic positions/velocities for simulations in adjacent Voronoi cells. Users may also optionally set the plugin to compute MMVT rate matrices, incubation time vectors, and other quantities needed in post-processing analysis and then update them all to a file with each collision. There is negligible slowdown caused by this feature and can be used to compute convergence and other quantities "on-the-fly".

The SEEKR2 Application Programming Interface (API). We include additional scripts and programs (called the API) for preparation, running, and analysis of the simulations. For preparation of the SEEKR2 calculation, we include a utility that prepares the file tree and files for a SEEKR2 calculation, typically using concentric spherical milestones defined by the distance between the center of mass (COM) of atoms of a receptor binding site and the COM of a ligand molecule, as was used in our first MMVT SEEKR paper.⁴⁶ For the convenient control of the SEEKR2 calculation, we include software that can be called with a single line that can run the simulations for any or all of the anchors and simulation regions. Last, we include an analysis package that will perform the milestone calculations to obtain mean first passage times, rate constants, free energy profiles, and other quantities that are potentially desirable to obtain from a SEEKR2 calculation. Automated programs are also included to compute convergence.

In addition to these utilities, a number of example calculation scripts are included as well as comprehensive unit tests, documentation, and tutorials, all within a MolSSI cookiecutter, which we found at <https://github.com/MolSSI/cookiecutter-cms.git>. Within the API, it is possible to define a milestone as a type from a growing list of possible shapes. While all the milestones in this study are concentric spheres, it is also currently possible in SEEKR2 to connect milestones of non-concentric spherical shapes, planar milestones, milestones that are a linear, weighted function of distances, angles, and dihedral order parameters, and milestones that depend on the RMSD of a set of atoms to a reference structure. Simple examples of API usage may be found at https://seekr2.readthedocs.io/en/latest/api_examples.html.

RESULTS AND DISCUSSION

Benchmarking was performed to compare the performance of SEEKR2 against the original MMVT-SEEKR implementation in NAMD and a conventional OpenMM simulation of the same molecular system. Comparisons are listed in Table 1. For

Table 1. Trypsin-Benzamidine System Performance (~23,000 Atoms)

MD engine	SEEKR version	computing resource	performance (ns/day)
NAMD2.13	MMVT SEEKR	Expanse V100 GPU (10 CPUs)	22
		Stampede CPU node (68 CPUs)	47
OpenMM7.5	SEEKR2	Expanse V100 GPU (1 CPU)	300
	conventional	Expanse V100 GPU (1 CPU)	416
	SEEKR2 with HMR	Expanse V100 GPU (1 CPU)	586

the trypsin-benzamidine system, the SEEKR2 OpenMM implementation performs almost 20 times faster than the NAMD-based MMVT-SEEKR code running on a GPU, which were re-run for the purposes of this study, and almost 6 times faster than the old MMVT-SEEKR running on a 68-core CPU node.⁴⁶ The differences between the performances of the newer OpenMM approach and the use of NAMD for the MD portion of the SEEKR2 calculations are primarily caused by the implementation of the CUDA code to perform the milestone

procedure directly in an OpenMM plugin. In contrast, the NAMD approach currently utilizes a TCL-based interface, which negatively impacts the speed of milestone calculations, even when the milestone crossings are only monitored every 10 timesteps. The NAMD3 program can run MD simulations on GPUs very efficiently, on-par with the speed of OpenMM on GPUs. However, at the time of this writing, NAMD3 has not implemented the TCL interface required to run milestone, so we are currently limited to NAMD2, which, as can be seen from Table 1, does not run as efficiently on GPUs as OpenMM. Additionally, the OpenMM SEEKR2 plugin enables us to evaluate milestone crossings at every timestep while incurring little extra computational cost (as opposed to a default of milestone crossing evaluation every 10 timesteps when using NAMD). Compared to a conventional OpenMM simulation (without SEEKR2), only a $\sim 25\%$ loss of speed was observed for these systems when the milestone protocols were included in the SEEKR2 plugin.

To ensure that SEEKR2 correctly replicated the rate constants as predicted in the original MMVT-SEEKR implementation,⁴⁶ we repeated the host-guest and trypsin-benzamidine simulations in a nearly identical process (details listed in the Materials and Methods section) to obtain kinetic and thermodynamic quantities, which are reported in this section. In recent years, there has been an interest in studying the inhibitors of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, especially in cancer therapy. The JAK-STAT signaling pathway plays a critical role in regulating immune response, and any irregularities can lead to immune disorders. We demonstrate the ability of SEEKR2 to correctly estimate the extraordinarily long residence time of a novel ATP-competitive inhibitor of the JAK2-STAT5 signaling pathway.

Several of our previous papers have run SEEKR calculations on the trypsin-benzamidine system.^{44,46} In Table 2, the rate

Table 2. Thermodynamics and Kinetics of Binding Results Computed for the Trypsin-Benzamidine System in Current and Previous Studies

trypsin/ benzamidine	k_{on} ($\text{M}^{-1} \text{s}^{-1}$)	k_{off} (s^{-1})	ΔG_{bind} (kcal/mol)
experimental ⁵⁷	2.9×10^7	600 ± 300	-6.71 ± 0.05
SEEKR1 (2017) (ref)	$(2.1 \pm 0.3) \times 10^7$	83 ± 14	-7.4 ± 0.1
MMVT SEEKR (2020) (ref)	$(12.0 \pm 0.5) \times 10^7$	174 ± 9	-7.9 ± 0.04
SEEKR2 (2022)	$(2.4 \pm 0.2) \times 10^7$	990 ± 130	-5.98 ± 0.09
SEEKR2 HMR (2022)	$(8.6 \pm 0.7) \times 10^6$	310 ± 30	-6.06 ± 0.08

constants for those calculations are listed alongside the values computed using the SEEKR2 program. SEEKR2 obtains a k_{off} and a k_{on} that are within an order of magnitude of the experimentally measured quantities. Compared to previous versions of SEEKR, and compared to the experimental values, SEEKR2 without HMR obtains a k_{off} that is slightly too fast ($990 \pm 130 \text{ s}^{-1}$ from SEEKR2 compared to experimental⁵⁷ $600 \pm 300 \text{ s}^{-1}$). The k_{on} obtained by SEEKR2 is very close relative to experiment ($(2.4 \pm 0.2) \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$ from SEEKR2 compared to the $2.9 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$ from experiment⁵⁷). Finally, the ΔG_{bind} computed by SEEKR2 was off by a little more than 0.8 kcal/mol ($-5.98 \pm 0.09 \text{ kcal/mol}$ from SEEKR2 compared to $-6.71 \pm 0.05 \text{ kcal/mol}$ from the experiment⁵⁷).

Additional convergence analyses are reported in the Supporting Information for both the k_{off} (Figure S1) and the k_{on} (Figure S2). For the trypsin-benzamidine system, the total steered molecular dynamics (SMD) simulation time was 20 ns, the total MD MMVT simulation time was $5 \mu\text{s}$, and 2 million BD trajectories were performed, in total. This is slightly more than the $4.4 \mu\text{s}$ of MD simulation time in our previous MMVT study.⁴⁶ The simulations in this study were lengthened to obtain a round 500 ns per anchor, a simple choice in contrast with our previous MMVT study, which ended simulations as they satisfied a convergence metric resulting in arbitrary simulation lengths in each anchor. In addition, the SEEKR2 calculations were run with desolvation forces activated for the BD stage. This required us to adjust the outermost milestones of the trypsin-benzamidine system and even add a new milestone with a 16 \AA radius. Without making this modification for SEEKR2, the desolvation forces and rigid body dynamics of BD prevented any reaction events from being observed, an issue that was not present for the MMVT-SEEKR version. Nevertheless, we believe that the desolvation forces add meaningful accuracy to the calculation, provided that the outermost milestone extends far enough into the solvent.

Results for the trypsin-benzamidine system when using HMR were fairly close to non-HMR and experimental values, yielding a k_{off} of $310 \pm 30 \text{ s}^{-1}$, a k_{on} of $(8.6 \pm 0.7) \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$, and a ΔG_{bind} of $-6.06 \pm 0.08 \text{ kcal/mol}$. These results indicate that HMR is able to compute similar binding kinetics at half the cost of conventional MD (Table 1).

In addition to the trypsin-benzamidine system, previous SEEKR studies have focused on computing the kinetics of a so-called "host-guest" model system, composed of the β -cyclodextrin and a series of small organic molecules.^{47,58} Using SEEKR2, as we did with MMVT SEEKR, we divided the space surrounding the β -cyclodextrin into 12 concentric spherical Voronoi cells (Figure 1) and recomputed k_{off} (Figure 2), k_{on} (Figure 3), and ΔG_{bind} values (Figure 4) for the seven




Figure 1. The space surrounding the β -cyclodextrin molecule is divided into 12 concentric spherical Voronoi tessellations (eight of the innermost ones are shown here), with boundaries that exist at 1 \AA increments from 1 to 13 \AA . OpenMM is used to run MMVT using MD within each of these cells, and trajectories collide against the boundaries between each cell, giving the transition times and statistics, which are analyzed with milestone theory. This image was generated using VMD.⁶⁵




Figure 2. The k_{off} s of each of the “guest” molecules to dissociate from the “host” molecule are listed. The “Experimental”, “Brute Force MD”, “SEEKR1”, and “MMVT SEEKR” results were generated in previous studies by others or us. The results labeled “SEEKR2” were generated in this study. SEEKR2 performs comparably or better than brute force MD and other computational methods. SEEKR2 is also the only method (aside from brute force MD) that correctly ranks the “guest” compounds by k_{off} according to the experiment. Error bars are present for the SEEKR2 data, but they are sometimes too small to see in this figure.

ligands mentioned in previous publications, both with and without HMR.^{46,47,58} SEEKR2, both with and without HMR, now correctly ranks the compounds by k_{off} . SEEKR2 also represents a substantial improvement in the calculations of absolute k_{on} s for the host–guest system, although SEEKR2 does not correctly rank k_{on} s for all seven host–guest systems, which is difficult for any method since the host–guest k_{on} s differ by magnitudes that are relatively small compared to experimental margins of error. The ΔG_{bind} values were computed with fairly similar accuracy to previous calculations, with the exception of aspirin, which showed an anomalous ΔG_{bind} value. It is likely that the noise seen in the k_{on} and ΔG_{bind} calculations is primarily caused by the concentric spherical milestone shapes used in this study, which may not adequately approximate isosurfaces of the committor function for the host–guest system, as would be produced by exact milestoning theory.²³ Additional milestone shapes have only been recently implemented in SEEKR2, which will allow us to investigate whether other types of milestones will improve the accuracy of k_{on} calculations for the host–guest system. For each individual host–guest system, the cost of the SMD simulations to generate a starting structure was 110 ns, and the MD MMVT ran for 700 ns each as well as 110,000 BD trajectories per guest molecule. This is slightly longer than the ~ 560 ns total MD of our previous MMVT study.⁴⁶ The reason for this is similar to the trypsin-benzamidine system above; the host–guest simulations in our previous study were halted after arbitrary times based on the satisfaction of a convergence

metric. In this study, we elected to extend the simulations to 50 ns per anchor, for all host–guest systems, to simplify and standardize the calculation. As with trypsin-benzamidine, HMR was able to successfully predict binding kinetics for the host–guest systems at a reduced computational cost. The HMR-predicted kinetics were close to experimental values, albeit somewhat different from the results obtained using non-HMR simulations, although within experimental error and without sacrificing correct rankings, in the case of host–guest k_{off} s. These results further demonstrate the utility of HMR to predict binding kinetics with associated cost savings using SEEKR2.

For the JAK protein in complex with ligand 6,⁵⁹ we generated 22 concentric spherical Voronoi cells, whose milestone radii were chosen to produce adequate sampling and favorable boundary collisions within each cell. Using this setup, we computed the k_{off} value (and residence time, by extension) for the JAK inhibitor (Figure 5) in four separate SEEKR runs (with the same settings and starting structures for each anchor), yielding an average k_{off} of $4.6 \pm 0.1 \times 10^{-5} \text{ s}^{-1}$ or a residence time of $6.3 \pm 0.1 \text{ h}$. The SEEKR-computed residence time is remarkably similar to an experimental residence time of 6.65 h for this system.⁵⁹ The residence time computed with SEEKR and reported here is the average of four separate runs from the same starting structures. The results of the individual runs as well as an examination of calculation sensitivity to different procedures used to compute




Figure 3. The k_{on} s of each “guest” compound as they bind to the “host” molecule are shown in order of increasing experimentally measured k_{on} . Previous studies had produced the “Experimental”, “Brute Force MD”, “SEEKR1”, and “MMVT SEEKR” results. The results of this study only produced the results labeled “SEEKR2”. SEEKR2 performs the best of all methods for estimating absolute k_{on} values. No methods were able to correctly rank k_{on} s. This is likely due to the very small differences between experimentally measured k_{on} s. Error bars are present for the SEEKR2 data, but they are sometimes too small to see in this figure.

the starting structures can be found in the [Supporting Information](#).

At this point, let us address the differences between error margins and convergence reported by SEEKR2 calculations. The apparent discrepancy between these two concepts can be clearly observed in [Figures 2–4](#), where SEEKR2 appears to estimate the rate constants with very high precision, but the estimated quantities appear to bear differences from one another. Error margins mainly depend on the shape of distributions of rate matrices, where the likelihood of a matrix is computed based on the statistics, counts, and times of transitions between milestones observed in simulation (the details of this computation may be found in the [Supporting Information](#)). In contrast, the convergence of results depends heavily on how well sampled are the relevant states in a simulation. A new user to SEEKR2 may be uncertain when sufficient simulation time has been obtained to compute kinetic and thermodynamic quantities of high quality for their system. In our experience, at least 250 ns, and often as much as 500 or 1000 ns, are needed to obtain converged SEEKR calculations. Once each anchor has this amount of simulation time, one should use `converge.py` to plot the convergence of k_{off} , k_{on} , or ΔG_{bind} , where convergence may be visually assessed. We believe that it is reasonable to declare a quantity as converged if its fluctuations lie within 10% of its mean value over a significant period of simulation time—for example, 200 ns. One should also confirm that sufficient transitions have

occurred between surfaces—ideally at least 100 intersurface transitions.

A system may transit between a series of energy basins, and all of these regions must be sampled thoroughly if good convergence is to be expected. Therefore, one may imagine the hypothetical situation where many transitions between milestones have been observed, but there was sufficient time in the trajectory to sample only one of multiple important energy basins—yielding small error margins but wide convergence errors. SEEKR2 includes additional tools, such as `converge.py`, that allow users to better analyze the quality of convergence for their system of interest.

We have included a flow chart diagram in the [Supporting Information](#) that details the inputs and the main steps of the SEEKR2 computation ([Figure S3](#)).

CONCLUSIONS

In summary, SEEKR2 performs MMVT and conventional milestone simulations with an extensible interface for milestone/Voronoi cell definitions and performs the simulations using either a CPU platform, or, much more quickly and efficiently, using a GPU platform. Only results using one-dimensional concentric spherical milestone shapes have been used for this study, but more dimensions and other milestone shapes have been implemented and will be straightforward to utilize. We have shown that SEEKR2, in general, performs better than earlier versions of SEEKR to recreate the kinetics




Figure 4. The ΔG_{bind} of each “guest” compound when binding to the “host” molecule ranked from lowest to highest ΔG_{bind} . The quantities marked as “Experiment”, “Kin. Experiment”, “Brute Force MD”, “SEEKR1”, and “MMVT SEEKR” were published in previous studies. Only the quantities labeled “SEEKR2” were generated in this study. Note that two experimental values are listed—one where the ΔG_{bind} was measured directly, and one where ΔG_{bind} was computed from the experimentally measured k_{on} and k_{off} . SEEKR2 correctly predicts compound ranking, with the exception of the first two compounds, which have very similar ΔG_{bind} . Error bars are present for the SEEKR2 data, but they are sometimes too small to see in this figure.




Figure 5. JAK2 protein (A) and its inhibitor, ligand 6 (B).

and thermodynamics for two benchmark systems and has performed well on a new, challenging system with a complex ligand and slow unbinding kinetics. The new HMR feature allows for even faster calculations while still giving correct results for the systems in this study. Additional work will need

to further validate the correctness of using HMR in simulations used to compute kinetics and under what circumstances HMR is suitable for that task. SEEKR2 contains many of the utilities that members of the biophysics community may find useful for their own milestone calculations.

MATERIALS AND METHODS

The SEEKR2 calculations in this paper required both MD and BD simulations, which accept different sorts of inputs. The analysis (calculation of kinetic and thermodynamic quantities, error analysis, and convergence analysis) was performed by SEEKR2. When possible, temperatures, salt concentrations, and protonation states were set to recreate experimental conditions as closely as possible. One exception to this was the MD simulations of the β -cyclodextrin “host” with the 1- or 2-naphthylethanol “guest”, which had 0.5 M MnSO_4 dissolved in solution for the experiment.⁶⁰ Due to the inadequacy or lack of parameters for these divalent ions, we elected to use pure water in these MD simulations, as we did with the other host–guest systems, which is consistent with previous studies.^{58,61} We also choose not to add the divalent salts to the BD stage as the use of divalent ions with the Poisson–Boltzmann equation was likely to cause inaccuracies. All ΔG_{bind} values were computed using the formula $\Delta G_{\text{bind}} = RT \ln(k_{\text{off}}/k_{\text{on}})$, where R is the gas constant, T is the temperature, and $\ln()$ is the natural logarithm function.

Molecular Dynamics Simulations. All MD were performed with OpenMM using the SEEKR2 OpenMM Plugin. Simulations were initiated through the SEEKR2 API. MMVT simulations were performed according to the prescribed procedure.⁶² All starting structures and parameters were reused from the previous SEEKR MMVT study, and the same collective variable definitions, site locations, and concentric spherical milestone shapes were used.⁴⁶

Brownian Dynamics Simulations. All BD were performed using the Browndye 2 program.⁶³ As with OpenMM, all simulations were prepared and controlled through the SEEKR API. Interior dielectrics were set to 4, while exterior dielectric constants were set to 78. All atomic positions, charges, and radii were reused from the previous SEEKR-MMVT study. The APBS program was used to compute electrostatic grids.⁶⁴ Desolvation forces and hydrodynamic interactions were enabled for all calculations, and other physical quantities (such as viscosity, solvent radius, etc.) were left at their defaults.

Trypsin-Benzamidine System. Simulations of the trypsin-benzamidine system were performed in an almost identical fashion to our previous study, in which we parametrized the protein using the AMBER ff14SB forcefield, and the ligand with Antechamber,⁴⁶ with all simulations performed at 298.15 K and, in the MD simulations, with rigid hydrogen-heavy atom bonds, and a non-bonded cutoff of 9 Å, and a timestep of 2 fs (4 fs for HMR), using OpenMM. The OpenMM implementation allowed us to check for a collision every timestep, instead of every 10 timesteps of the previous implementation,⁴⁶ which likely improved calculation accuracy. We added some additional milestones to the trypsin-benzamidine system such that milestones were located at 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, and 18 Å from the center of mass of the binding site. Starting structures within each Voronoi cell were generated from an SMD simulation, where the system was started from a bound state configuration and pulled out to a site ligand from a distance of 1 Å to a distance of 13 Å over the course of 20 ns of constant volume (NVT) MD using a moving harmonic restraint with a spring constant of 9000 $\text{kJ}\cdot\text{mol}^{-1}\cdot\text{nm}^{-2}$. Upon examination, we determined that the original 14 Å milestones showed anomalous results in the BD, probably due to solvation shell effects and steric

hindrances caused by the rigid body approach in BD. We added milestones beyond the original 14 Å to improve the calculation by moving the BD region beyond the solvation shells. Starting structures beyond the 14 Å milestone were extracted sequentially from the states generated at the moments of MMVT collisions against lower milestones. Using the generated starting structures for each Voronoi cell, a total of 500 ns of MMVT MD simulations per cell were performed using SEEKR2. All collisions against the milestones were recorded for later analysis. For the BD simulations, the ligand was started at the b-surface and proceeded until it either escaped or satisfied the “reaction criteria” of touching the 18 Å radius milestone (b-surface stage). Then, among those that touched the 18 Å milestone, 1000 structures were extracted, and from each of these, 1000 independent BD simulations were run until the ligands either escaped or touched the 16 Å milestone (BD milestone stage). The purpose of the b-surface stage is to compute the rate of initial encounter with the outermost milestone, while the BD milestone stage computes transition probabilities used in the milestone model, which are used, in combination with the initial encounter rate, to compute the k_{on} .

Host–Guest Systems. For the host–guest systems, all parameters and starting structures were identical to our previous SEEKR papers where we used the Q4MD forcefield for host and guest parametrizations.^{46,47} However, to better recreate experimental conditions, a few adjustments to the host–guest system simulations were necessary. The conditions used to generate the experimental quantities are summarized in Table 3. In previous studies, all SEEKR calculations had been

Table 3. Experimental Conditions when Measuring the Kinetics of Binding/Unbinding for the Host–Guest System^a

guest molecule	experimental study	temperature (K)	salt	pH
1-propanol	Fukahori et al. ⁶⁶	298.15	pure water	7
1-butanol	Fukahori et al. ⁶⁶	298.15	pure water	7
<i>tert</i> -butanol	Fukahori et al. ⁶⁶	298.15	pure water	7
1-naphthyl-ethanol	Barros et al. ⁶⁰	293.15	0.5 M MnSO_4	7
2-naphthyl-ethanol	Barros et al. ⁶⁰	293.15	0.5 M MnSO_4	7
methyl butyrate	Nishikawa et al. ⁶⁷	298.15	pure water	7
aspirin (protonated)	Fukahori et al. ⁶⁸	298.15	pure water	1.7

^aWe attempted to recreate these conditions as closely as possible in our simulations/calculations.

performed at 298.15 K, but in this study, we simulated the 1-naphthyl-ethanol and 2-naphthyl-ethanol guest compounds at 293.15 K to match experiment more closely. As in our previous study, we elected to perform all MD and BD simulations in pure water due to the difficulty of correctly representing divalent electrolytes in MD and also in the Poisson–Boltzmann formulation used in BD.

New SMD simulations were performed where the centers of masses (COMs) of “guest” ligands were restrained to 0.5 Å from the COM of the β -cyclodextrin “host” for 10 ns of constant pressure MD (NPT). Following this, the guest molecules were pulled by a moving harmonic restraint with a spring constant of 90,000 $\text{kJ}\cdot\text{mol}^{-1}\cdot\text{nm}^{-2}$ in an SMD

simulation from the 0.5 Å starting location to a final COM-COM distance of 13.5 over the course of 100 ns of NVT MD. The purpose of the SMD simulations was to generate starting structures between each pair of milestones (near the center of each Voronoi cell). Using these starting structures for the MD simulations, MMVT simulations were run using SEEKR for 50 ns per Voronoi cell, which is equal to the maximum simulation length per anchor of the previous MMVT study we performed.⁴⁶ BD simulations of both the b-surface stage and the BD milestone stage were run to compute host–guest k_{on} s.

JAK Systems. The starting structure was obtained from the X-ray crystal structure of the JAK2-inhibitor complex domain with PDB ID: 3ZMM. Forcefield parameterization was done using the AMBER ff14SB forcefield with explicit solvation in a truncated octahedron 10 Å periodic box, 150 mM salt concentration, and a non-bonded cut-off radius of 9 Å. The ligand was parametrized using Antechamber in AmberTools with partial charges assigned by the AM1-BCC semiempirical charge model and all other parameters assigned from GAFF. The solvated complex was slowly heated to 300 K followed by 20 ns each of NPT and NVT MD preparatory simulation carried out at 300 K. All MD simulations have been carried out using the OpenMM simulation engine. SMD simulations were then performed where the COM of the inhibitor was restrained to 2.5 Å from the COM of the binding region of the receptor for 20 ns of constant pressure MD (NPT). Subsequently, the inhibitor was pulled by a moving harmonic restraint with a spring constant of 50,000 kJ·mol⁻¹·nm⁻² in an SMD simulation from the 2.5 Å starting location to a final COM-COM distance of 16.0 Å over the course of 1000 ns of NVT MD. Concentric spherical Voronoi cells or “milestones” were defined at distances of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, and 16.0 Å from the COM of the binding site. MMVT simulations were then run using SEEKR for 400 ns per Voronoi cell.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jcim.2c00501>.

Additional data, figures, tables, and equations including a formulation of MMVT error analysis, convergence of the k_{off} and k_{on} for the trypsin-benzamidine system, the workflow diagram of the SEEKR2 procedure, and results of four separate runs of the JAK system can be found in the SI (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Rommie E. Amaro – University of California, San Diego, La Jolla, California 92093, United States; orcid.org/0000-0002-9275-9553; Email: ramaro@ucsd.edu

Authors

Lane W. Votapka – University of California, San Diego, La Jolla, California 92093, United States

Andrew M. Stokely – University of California, San Diego, La Jolla, California 92093, United States; orcid.org/0000-0002-3750-5323

Anupam A. Ojha – University of California, San Diego, La Jolla, California 92093, United States; orcid.org/0000-0001-6588-3092

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acs.jcim.2c00501>

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. L.W.V. and A.M.S. coded the SEEKR2 API and OpenMM plugin. L.W.V. ran the non-HMR host–guest and trypsin-benzamidine calculations, wrote the text of the manuscript, and made tables and some figures. A.M.S. performed all HMR simulations and contributed to the writing, editing, and some figures. A.A.O. completed all calculations on the JAK system, tested the SEEKR2 code, and contributed to writing and bug fixes. R.E.A. is the principal investigator of the project, providing the resources, funding, environment, and guidance on the project as well as some of the manuscript writing and editing.

Funding

This work was funded in part by the National Science Foundation through XSEDE supercomputing resources provided via TG-CHE060073 to R.E.A. A.A.O. acknowledges support from the Molecular Sciences Software Institute (MolSSI) fellowship under NSF grant OAC-1547580.

Notes

The authors declare no competing financial interest. SEEKR2 can be found at <https://github.com/seekrcentral/seekr2.git>, which also includes documentation about installation instructions and several tutorials for how to prepare and use SEEKR2 to compute the kinetics and thermodynamics of molecular systems of interest. The SEEKR2 OpenMM plugin can be found at https://github.com/seekrcentral/seekr2_openmm_plugin.git. The data for this study can be obtained at <https://doi.org/10.6075/J0668DDR>.

■ ACKNOWLEDGMENTS

We thank J. Andrew McCammon, Surl-Hee (Shirley) Ahn, and Gary Huber for insightful and helpful discussions. We also thank Benjamin Jagger for providing useful content, code, advice, and feedback on the manuscript. We also thank Jeffrey Wagner for assistance with the Github repository and Ilker Deveci and Hilliary Frank for testing and assistance with the documentation for SEEKR2.

■ ABBREVIATIONS

SEEKR2, simulation-enabled estimation of kinetic rates version 2; MMVT, Markovian milestoning with Voronoi tessellations; MD, molecular dynamics; BD, Brownian dynamics; COM, center of mass; NVT, constant number of particles, volume, and temperature simulation; NPT, constant number of particles, pressure, and temperature simulation; API, application programming interface

■ REFERENCES

- (1) Swinney, D. C. Biochemical Mechanisms of Drug Action: What Does It Take for Success? *Nat. Rev. Drug Discov.* **2004**, *3*, 801.
- (2) Schuetz, D. A.; de Witte, W. E. A.; Wong, Y. C.; Knasmueller, B.; Richter, L.; Kokh, D. B.; Sadiq, S. K.; Bosma, R.; Nederpelt, I.; Heitman, L. H.; Segala, E.; Amaral, M.; Guo, D.; Andres, D.; Georgi, V.; Stoddart, L. A.; Hill, S.; Cooke, R. M.; De Graaf, C.; Leurs, R.; Frech, M.; Wade, R. C.; de Lange, E. C. M.; IJzerman, A. P.; Müller-Fahrnow, A.; Ecker, G. F. Kinetics for Drug Discovery: An Industry-Driven Effort to Target Drug Residence Time. *Drug Discovery Today* **2017**, *22*, 896.

- (3) Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug–Target Residence Time and Its Implications for Lead Optimization. *Nat. Rev. Drug Discov.* **2006**, *5*, 730.
- (4) Tummino, P. J.; Copeland, R. A. Residence Time of Receptor–Ligand Complexes and Its Effect on Biological Function. *Biochemistry* **2008**, *47*, 5481.
- (5) Copeland, R. A. The Drug–Target Residence Time Model: A 10-Year Retrospective. *Nat. Rev. Drug Discov.* **2016**, *15*, 87.
- (6) Lu, H.; Tonge, P. J. Drug–Target Residence Time: Critical Information for Lead Optimization. *Curr. Opin. Chem. Biol.* **2010**, *14*, 467.
- (7) Romanowska, J.; Kokh, D. B.; Fuller, J. C.; Wade, R. C. Computational Approaches for Studying Drug Binding Kinetics. In *Thermodynamics and Kinetics of Drug Binding*; John Wiley & Sons, Ltd, 2015; pp. 211–235, DOI: 10.1002/9783527673025.ch11.
- (8) De Vivo, M.; Masetti, M.; Bottegoni, G.; Cavalli, A. Role of Molecular Dynamics and Related Methods in Drug Discovery. *J. Med. Chem.* **2016**, *59*, 4035.
- (9) Bruce, N. J.; Ganotra, G. K.; Kokh, D. B.; Sadiq, S. K.; Wade, R. C. New Approaches for Computing Ligand–Receptor Binding Kinetics. *Curr. Opin. Struct. Biol.* **2018**, *49*, 1.
- (10) Lee, C. T.; Amaro, R. E. Exascale Computing: A New Dawn for Computational Biology. *Comput. Sci. Eng.* **2018**, *20*, 18.
- (11) Shaw, D. E.; Bowers, K. J.; Chow, E.; Eastwood, M. P.; Ierardi, D. J.; Klepeis, J. L.; Kuskin, J. S.; Larson, R. H.; Lindorff-Larsen, K.; Maragakis, P.; Moraes, M. A.; Dror, R. O.; Piana, S.; Shan, Y.; Towles, B.; Salmon, J. K.; Grossman, J. P.; Mackenzie, K. M.; Bank, J. A.; Young, C.; Deneroff, M. M.; Batson, B. Millisecond-Scale Molecular Dynamics Simulations on Anton. In *Proceedings of the Conference on High Performance Computing Networking, Storage and Analysis - SC '09*; ACM Press: New York: New York, USA, 2009; p 1, DOI: 10.1145/1654059.1654126.
- (12) Shaw, D. E.; Grossman, J. P.; Bank, J. A.; Batson, B.; Butts, J. A.; Chao, J. C.; Deneroff, M. M.; Dror, R. O.; Even, A.; Fenton, C. H.; Forte, A.; Gagliardo, J.; Gill, G.; Greskamp, B.; Ho, C. R.; Ierardi, D. J.; Iserovich, L.; Kuskin, J. S.; Larson, R. H.; Layman, T.; Lee, L. S.; Lerer, A. K.; Li, C.; Killebrew, D.; Mackenzie, K. M.; Mok, S. Y. H.; Moraes, M. A.; Mueller, R.; Nociolo, L. J.; Peticolas, J. L.; Quan, T.; Ramot, D.; Salmon, J. K.; Scarpazza, D. P.; Ben Schafer, U.; Siddique, N.; Snyder, C. W.; Spengler, J.; Tang, P. T. P.; Theobald, M.; Toma, H.; Towles, B.; Vitale, B.; Wang, S. C.; Young, C. Anton 2: Raising the Bar for Performance and Programmability in a Special-Purpose Molecular Dynamics Supercomputer. In *International Conference for High Performance Computing, Networking, Storage and Analysis, SC; IEEE*, 2014; Vol. 2015-Janua, pp. 41–53, DOI: 10.1109/SC.2014.9.
- (13) Shan, Y.; Kim, E. T.; Eastwood, M. P.; Dror, R. O.; Seeliger, M. A.; Shaw, D. E. How Does a Drug Molecule Find Its Target Binding Site? *J. Am. Chem. Soc.* **2011**, *133*, 9181.
- (14) Dror, R. O.; Pan, A. C.; Arlow, D. H.; Borhani, D. W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D. E. Pathway and Mechanism of Drug Binding to G-Protein-Coupled Receptors. *Proc. Natl. Acad. Sci.* **2011**, *108*, 13118.
- (15) Pan, A. C.; Borhani, D. W.; Dror, R. O.; Shaw, D. E. Molecular Determinants of Drug–Receptor Binding Kinetics. *Drug Discovery Today* **2013**, *18*, 667.
- (16) Huang, D.; Caffisch, A. The Free Energy Landscape of Small Molecule Unbinding. *PLoS Comput. Biol.* **2011**, *7*, e1002002.
- (17) Buch, I.; Giorgino, T.; De Fabritiis, G. Complete Reconstruction of an Enzyme–Inhibitor Binding Process by Molecular Dynamics Simulations. *Proc. Natl. Acad. Sci.* **2011**, *108*, 10184.
- (18) Ermak, D. L.; McCammon, J. A. Brownian Dynamics with Hydrodynamic Interactions. *J. Chem. Phys.* **1978**, *69*, 1352.
- (19) Northrup, S. H.; Allison, S. A.; McCammon, J. A. Brownian Dynamics Simulation of Diffusion-Influenced Bimolecular Reactions. *J. Chem. Phys.* **1984**, *80*, 1517.
- (20) McCammon, J. A.; Northrup, S. H.; Allison, S. A. Diffusional Dynamics of Ligand–Receptor Association. *J. Phys. Chem.* **1986**, *90*, 3901.
- (21) Northrup, S. H.; Erickson, H. P. Kinetics of Protein–Protein Association Explained by Brownian Dynamics Computer Simulation. *Proc. Natl. Acad. Sci. U. S. A.* **1992**, *89*, 3338.
- (22) Luty, B. A.; McCammon, J. A.; Zhou, H. X. Diffusive Reaction Rates from Brownian Dynamics Simulations: Replacing the Outer Cutoff Surface by an Analytical Treatment. *J. Chem. Phys.* **1992**, *97*, 5682.
- (23) Bello-Rivas, J. M.; Elber, R. Exact Milestoning. *J. Chem. Phys.* **2015**, *142*, 03B602_1.
- (24) Elber, R. A New Paradigm for Atomically Detailed Simulations of Kinetics in Biophysical Systems. *Q. Rev. Biophys.* **2017**, *50*, DOI: 10.1017/S0033583517000063.
- (25) Doerr, S.; de Fabritiis, G. On-the-Fly Learning and Sampling of Ligand Binding by High-Throughput Molecular Simulations. *J. Chem. Theory Comput.* **2014**, *10*, 2064.
- (26) Prinz, J. H.; Wu, H.; Sarich, M.; Keller, B.; Senne, M.; Held, M.; Chodera, J. D.; Schütte, C.; Noé, F. Markov Models of Molecular Kinetics: Generation and Validation. *J. Chem. Phys.* **2011**, *134*, 174105.
- (27) Jagger, B. R.; Kochanek, S. E.; Haldar, S.; Amaro, R. E.; Mulholland, A. J. Multiscale Simulation Approaches to Modeling Drug–Protein Binding. *Curr. Opin. Struct. Biol.* **2020**, *61*, 213.
- (28) Bernetti, M.; Masetti, M.; Recanatini, M.; Amaro, R. E.; Cavalli, A. An Integrated Markov State Model and Path Metadynamics Approach To Characterize Drug Binding Processes. *J. Chem. Theory Comput.* **2019**, *15*, 5689.
- (29) Aristoff, D.; Lelièvre, T.; Mayne, C. G.; Teo, I. Adaptive Multilevel Splitting in Molecular Dynamics Simulations. *ESAIM: Proc.* **2015**, *48*, 215.
- (30) Teo, I.; Mayne, C. G.; Schulten, K.; Lelièvre, T. Adaptive Multilevel Splitting Method for Molecular Dynamics Calculation of Benzamidine–Trypsin Dissociation Time. *J. Chem. Theory Comput.* **2016**, 2983.
- (31) Limongelli, V.; Bonomi, M.; Parrinello, M. Funnel Metadynamics as Accurate Binding Free-Energy Method. *Proc. Natl. Acad. Sci.* **2013**, *110*, 6358.
- (32) Raniolo, S.; Limongelli, V. Ligand Binding Free-Energy Calculations with Funnel Metadynamics. *Nat. Protoc.* **2020**, *15*, 2837.
- (33) Huber, G. A.; Kim, S. Weighted-Ensemble Brownian Dynamics Simulations for Protein Association Reactions. *Biophys. J.* **1996**, *70*, 97.
- (34) Darve, E.; Ryu, E. Chapter 7 Computing Reaction Rates in Bio-Molecular Systems Using Discrete Macro-States. In *Innovations in Biomolecular Modeling and Simulations: Volume 1*; The Royal Society of Chemistry, 2012; Vol. 1, pp. 138–206, DOI: 10.1039/9781849735049-00138.
- (35) Dickson, A.; Brooks, C. L., III WExplore: Hierarchical Exploration of High-Dimensional Spaces Using the Weighted Ensemble Algorithm. *J. Phys. Chem. B* **2014**, *118*, 3532.
- (36) Amaro, R. E.; Mulholland, A. J. Bridging Biological and Chemical Complexity in the Search for Cures: Multiscale Methods in Drug Design. *Nat. Rev. Chem.* **2018**, *2*, 0148.
- (37) Tiwary, P.; Limongelli, V.; Salvalaglio, M.; Parrinello, M. Kinetics of Protein–Ligand Unbinding: Predicting Pathways, Rates, and Rate-Limiting Steps. *Proc. Natl. Acad. Sci.* **2015**, *112*, e386.
- (38) Bowman, G. R.; Pande, V. S.; Noé, F. *An Introduction to Markov State Models and Their Application to Long Timescale Molecular Simulation*; Bowman, G. R., Pande, V. S., Noé, F., Eds.; Advances in Experimental Medicine and Biology; Springer Netherlands: Dordrecht, 2014; Vol. 797, DOI: 10.1007/978-94-007-7606-7.
- (39) Gobbo, D.; Piretti, V.; Di Martino, R. M. C.; Tripathi, S. K.; Giabbai, B.; Storici, P.; Demitri, N.; Giroto, S.; Decherchi, S.; Cavalli, A. Investigating Drug–Target Residence Time in Kinases through Enhanced Sampling Simulations. *J. Chem. Theory Comput.* **2019**, *15*, 4646.
- (40) Wu, H.; Paul, F.; Wehmeyer, C.; Noé, F. Multiensemble Markov Models of Molecular Thermodynamics and Kinetics. *Proc. Natl. Acad. Sci.* **2016**, *113*, e3221.

- (41) Plattner, N.; Noé, F. Protein Conformational Plasticity and Complex Ligand-Binding Kinetics Explored by Atomistic Simulations and Markov Models. *Nat. Commun.* **2015**, *6*, 1.
- (42) Mollica, L.; Decherchi, S.; Zia, S. R.; Gaspari, R.; Cavalli, A.; Rocchia, W. Kinetics of Protein-Ligand Unbinding via Smoothed Potential Molecular Dynamics Simulations. *Sci. Rep.* **2015**, *5*, 1.
- (43) Mollica, L.; Theret, I.; Antoine, M.; Perron-Sierra, F.; Charton, Y.; Fourquez, J.-M.; Wierzbicki, M.; Boutin, J. A.; Ferry, G.; Decherchi, S.; Bottegoni, G.; Ducrot, P.; Cavalli, A. Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times. *J. Med. Chem.* **2016**, *59*, 7167.
- (44) Votapka, L. W.; Jagger, B. R.; Heyneman, A. L.; Amaro, R. E. SEEKR: Simulation Enabled Estimation of Kinetic Rates, A Computational Tool to Estimate Molecular Kinetics and Its Application to Trypsin-Benzamidine Binding. *J. Phys. Chem. B* **2017**, *121*, 3597.
- (45) Votapka, L. W.; Lee, C. T.; Amaro, R. E. Two Relations to Estimate Membrane Permeability Using Milestoning. *J. Phys. Chem. B* **2016**, *120*, 8606.
- (46) Jagger, B. R.; Ojha, A. A.; Amaro, R. E. Predicting Ligand Binding Kinetics Using a Markovian Milestoning with Voronoi Tessellations Multiscale Approach. *J. Chem. Theory Comput.* **2020**, *5348*.
- (47) Jagger, B. R.; Lee, C. T.; Amaro, R. E. Quantitative Ranking of Ligand Binding Kinetics with a Multiscale Milestoning Simulation Approach. *J. Phys. Chem. Lett.* **2018**, *9*, 4941.
- (48) Faradjian, A. K.; Elber, R. Computing Time Scales from Reaction Coordinates by Milestoning. *J. Chem. Phys.* **2004**, *120*, 10880.
- (49) West, A. M. A.; Elber, R.; Shalloway, D. Extending Molecular Dynamics Time Scales with Milestoning: Example of Complex Kinetics in a Solvated Peptide. *J. Chem. Phys.* **2007**, *126*, 04B608.
- (50) Vanden-Eijnden, E.; Venturoli, M.; Ciccotti, G.; Elber, R. On the Assumptions Underlying Milestoning. *J. Chem. Phys.* **2008**, *129*, 174102.
- (51) Bello-Rivas, J. M.; Elber, R. Simulations of Thermodynamics and Kinetics on Rough Energy Landscapes with Milestoning. *J. Comput. Chem.* **2016**, *37*, 602.
- (52) Votapka, L. W.; Amaro, R. E. Multiscale Estimation of Binding Kinetics Using Brownian Dynamics, Molecular Dynamics and Milestoning. *PLoS Comput. Biol.* **2015**, *11*, e1004381.
- (53) Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kalé, L.; Schulten, K. Scalable Molecular Dynamics with NAMD. *J. Comput. Chem.* **2005**, *26*, 1781.
- (54) Eastman, P.; Swails, J.; Chodera, J. D.; McGibbon, R. T.; Zhao, Y.; Beauchamp, K. A.; Wang, L.-P.; Simmonett, A. C.; Harrigan, M. P.; Stern, C. D.; Wiewiora, R. P.; Brooks, B. R.; Pande, V. S. OpenMM 7: Rapid Development of High Performance Algorithms for Molecular Dynamics. *PLoS Comput. Biol.* **2017**, *13*, e1005659.
- (55) Hopkins, C. W.; Le Grand, S.; Walker, R. C.; Roitberg, A. E. Long-Time-Step Molecular Dynamics through Hydrogen Mass Repartitioning. *J. Chem. Theory Comput.* **2015**, *11*, 1864.
- (56) Jung, J.; Kasahara, K.; Kobayashi, C.; Oshima, H.; Mori, T.; Sugita, Y. Optimized Hydrogen Mass Repartitioning Scheme Combined with Accurate Temperature/Pressure Evaluations for Thermodynamic and Kinetic Properties of Biological Systems. *J. Chem. Theory Comput.* **2021**, *17*, 5312.
- (57) Guillain, F.; Thusius, D. The Use of Proflavin as an Indicator in Temperature-Jump Studies of the Binding of a Competitive Inhibitor to Trypsin. *J. Am. Chem. Soc.* **1970**, *92*, 5534.
- (58) Tang, Z.; Chang, C. A. Binding Thermodynamics and Kinetics Calculations Using Chemical Host and Guest: A Comprehensive Picture of Molecular Recognition. *J. Chem. Theory Comput.* **2018**, *14*, 303.
- (59) Guan, H.; Lamb, M. L.; Peng, B.; Huang, S.; DeGrace, N.; Read, J.; Hussain, S.; Wu, J.; Rivard, C.; Alimzhanov, M.; Bebernitz, G.; Bell, K.; Ye, M.; Zinda, M.; Ioannidis, S. Discovery of Novel Jak2-Stat Pathway Inhibitors with Extended Residence Time on Target. *Chem. Lett.* **2013**, *23*, 3105.
- (60) Barros, T. C.; Stefaniak, K.; Holzwarth, J. F.; Bohne, C. Complexation of Naphthylethanols with β -Cyclodextrin. *J. Phys. Chem. A* **1998**, *102*, 5639.
- (61) Fenley, A. T.; Henriksen, N. M.; Muddana, H. S.; Gilson, M. K. Bridging Calorimetry and Simulation through Precise Calculations of Cucurbituril-Guest Binding Enthalpies. *J. Chem. Theory Comput.* **2014**, *10*, 4069.
- (62) Vanden-Eijnden, E.; Venturoli, M. Markovian Milestoning with Voronoi Tessellations. *J. Chem. Phys.* **2009**, *130*, 194101.
- (63) Huber, G.; McCammon, J. A. Brownian Dynamics Simulations of Biological Molecules. *Trends Chem.* **2019**, *1*, 727.
- (64) Jurrus, E.; Engel, D.; Star, K.; Monson, K.; Brandi, J.; Felberg, L. E.; Brookes, D. H.; Wilson, L.; Chen, J.; Liles, K.; Chun, M.; Li, P.; Gohara, D. W.; Dolinsky, T.; Konecny, R.; Koes, D. R.; Nielsen, J. E.; Head-Gordon, T.; Geng, W.; Krasny, R.; Wei, G.-W.; Holst, M. J.; McCammon, J. A.; Baker, N. A. Improvements to the APBS Biomolecular Solvation Software Suite. *Protein Sci.* **2018**, *27*, 112.
- (65) Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular Dynamics. *J. Mol. Graph.* **1996**, *14*, 33.
- (66) Fukahori, T.; Nishikawa, S.; Yamaguchi, K. Kinetics on Isomeric Alcohols Recognition by α - and β -Cyclodextrins Using Ultrasonic Relaxation Method. *Bull. Chem. Soc. Jpn.* **2004**, *77*, 2193.
- (67) Nishikawa, S.; Fukahori, T.; Ishikawa, K. Ultrasonic Relaxations in Aqueous Solutions of Propionic Acid in the Presence and Absence of β -Cyclodextrin. *J. Phys. Chem. A* **2002**, *106*, 3029.
- (68) Fukahori, T.; Kondo, M.; Nishikawa, S. Dynamic Study of Interaction between β -Cyclodextrin and Aspirin by the Ultrasonic Relaxation Method. *J. Phys. Chem. B* **2006**, *110*, 4487.